BRVE NASDAQ
Braveheart Bio, Inc.
1W: +1.4%
1M: +1.9%
YTD: +48.0%
$26.64
-0.61 (-2.24%)
Weekly Expected Move ±9.6%
$22
$24
$27
$29
$32
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$159.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range24.31-32
Volume283,590
Avg Volume468,981
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOTravis Murdoch
Employees30
SectorHealthcare
IndustryBiotechnology
IPO Date2026-08-06
Websitebraveheart.bio
One Letterman Drive, Building A, Suite A4-300
San Francisco, CA 94129
US
San Francisco, CA 94129
US
About Braveheart Bio, Inc.
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Latest News
Braveheart Bio, Inc. reports Q2 results
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio, Inc.’s Quiet Period To Expire on September 15th (NASDAQ:BRVE)
Insiders Are Betting Big on These 3 Healthcare Stocks
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Agarwala Vineeta | 0 | — | 2026-08-07 | |
| Chimovits Erez | C-Conversion | 9,132,420 | — | 2026-08-07 |
| Chimovits Erez | P-Purchase | 1,666,667 | $18.00 | 2026-08-07 |
| Chimovits Erez | P-Purchase | 273,333 | $18.00 | 2026-08-07 |
| Chimovits Erez | C-Conversion | 40,000,000 | — | 2026-08-07 |